ofloxacin has been researched along with Diabetic Feet in 9 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levofloxacin has a high bioavailability and a broad antibacterial spectrum which covers the common pathogens found in acute and chronic diabetic foot infections." | 7.72 | Tissue and serum levofloxacin concentrations in diabetic foot infection patients. ( Baertsch, U; Born, B; Geiss, HK; Hamann, A; Hoppe-Tichy, T; Kusterer, K; Oberdorfer, K; Swoboda, S; von Baum, H, 2004) |
| "Levofloxacin has a high bioavailability and a broad antibacterial spectrum which covers the common pathogens found in acute and chronic diabetic foot infections." | 3.72 | Tissue and serum levofloxacin concentrations in diabetic foot infection patients. ( Baertsch, U; Born, B; Geiss, HK; Hamann, A; Hoppe-Tichy, T; Kusterer, K; Oberdorfer, K; Swoboda, S; von Baum, H, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bogomolov, MS | 1 |
| Slobodianiuk, VV | 1 |
| Lipsky, BA | 2 |
| Holroyd, KJ | 1 |
| Zasloff, M | 1 |
| Taha, AB | 1 |
| Joshi, S | 2 |
| Maroli, S | 1 |
| Moulick, ND | 1 |
| Badhane, S | 1 |
| Sthalekar, N | 1 |
| Ambavane, V | 1 |
| Patil, R | 1 |
| Abhyankar, M | 1 |
| Dilip, P | 1 |
| Lobmann, R | 1 |
| Ambrosch, A | 1 |
| Seewald, M | 1 |
| Dietlein, M | 1 |
| Zink, K | 1 |
| Kullmann, KH | 1 |
| Lehnert, H | 1 |
| Oberdorfer, K | 1 |
| Swoboda, S | 1 |
| Hamann, A | 1 |
| Baertsch, U | 1 |
| Kusterer, K | 1 |
| Born, B | 1 |
| Hoppe-Tichy, T | 1 |
| Geiss, HK | 1 |
| von Baum, H | 1 |
| Baker, PD | 1 |
| Landon, GC | 1 |
| Fernau, R | 1 |
| Kuck, EM | 1 |
| Bouter, KP | 1 |
| Hoekstra, JB | 1 |
| Conemans, JM | 1 |
| Diepersloot, RJ | 1 |
| Senneville, E | 1 |
| Yazdanpanah, Y | 1 |
| Cazaubiel, M | 1 |
| Cordonnier, M | 1 |
| Valette, M | 1 |
| Beltrand, E | 1 |
| Khazarjian, A | 1 |
| Maulin, L | 1 |
| Alfandari, S | 1 |
| Caillaux, M | 1 |
| Dubreuil, L | 1 |
| Mouton, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Surgical Management of Diabetic Foot Infections - The Role of Post-Operative Antibiotics[NCT01539811] | 2 participants (Actual) | Interventional | 2012-02-29 | Terminated (stopped due to Principal investigator decided to terminate the study.) | |||
| MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers[NCT00563394] | Phase 3 | 584 participants (Actual) | Interventional | 1994-08-31 | Completed | ||
| MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers[NCT00563433] | Phase 3 | 342 participants (Actual) | Interventional | 1994-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for ofloxacin and Diabetic Feet
| Article | Year |
|---|---|
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacteria; Bacterial Infections; Diabetic Foo | 2008 |
Efficacy and tolerability of a combination of ofloxacin and tinidazole in the management of infectious diabetic foot ulcer.
Topics: Adult; Anti-Infective Agents; Antitrichomonal Agents; Diabetic Foot; Drug Therapy, Combination; Fema | 2003 |
Antibiotic therapy for diabetic foot infections: comparison of cephalosporines with chinolones.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Ceftriaxone; Ciprofloxa | 2004 |
Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Bacterial Agents | 1997 |
5 other studies available for ofloxacin and Diabetic Feet
| Article | Year |
|---|---|
[Treatment of trophic ulsers of different etiology].
Topics: Adult; Anesthetics, Local; Anti-Infective Agents, Local; Arteriosclerosis Obliterans; Bacteria; Diab | 2013 |
Relationship and susceptibility profile of Staphylococcus aureus infection diabetic foot ulcers with Staphylococcus aureus nasal carriage.
Topics: Adult; Aged; Anti-Bacterial Agents; Carrier State; Diabetic Foot; Female; Humans; Levofloxacin; Male | 2013 |
Tissue and serum levofloxacin concentrations in diabetic foot infection patients.
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Chromatography, High Pressure Liq | 2004 |
Tissue concentrations after a single-dose, orally administered ofloxacin in patients with diabetic foot infections.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Diabetic | 1998 |
Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Antibiotics, Antitubercular; Bacterial Infections | 2001 |